ESMO Advanced Course on Metastatic EGFR-Mutant NSCLC

Seoul, Korea, Republic of - 28 Oct - 29 Oct 2016

This ESMO advanced course was created to update and inform clinicians on the latest developments in the understanding of the development of resistance to TKI therapies, the genetic origins of the resistance and the latest diagnostic and clinical developments enabling the clinical management of resistance in NSCLC patients.

ESMO advanced courses provide state-of-the-art lectures in an interactive setting, made possible by providing ample time for delegates to present questions to the course faculty members and through the inclusion in the programme of highly interactive workshops.

Learning Objectives

  • To understand the biology and role of EGFR and TKI’s (1st, 2nd, 3rd generation) in the management of NSCLC
  • To understand the development of resistance to TKI’s and the available treatment options
  • To understand the role of T790M in the development of resistance
  • To understand the utility of different diagnostic methods in identifying the resistance mechanism
  • To understand the importance of the multidisciplinary team and particularly the pathologist and radiologists in optimising diagnosis and selection of the most appropriate treatment options

Access the slides on OncologyPRO


The programme was designed for medical oncologists, clinical oncologists, organ specialists, radiation oncologists, surgeons, pathologists and other members of multidisciplinary teams managing NSCLC patients. This event has been accredited with 9 ESMO-MORA CME Points.

Download the programme


Chair: Rolf A. Stahel, Switzerland
Local Chair: Keunchil Park, South Korea


Conrad Hotel Seoul
10 Gukjegeumyung-ro (Yeouido) Yeongdeungpo-gu
Seoul, 07326
South Korea


AstraZeneca provided a sponsorship grant towards this independent Programme.